The announcement that planning permission has finally been granted for Cambridge University's proposed world-class primate neuro-science centre has been welcomed by the Association of the British Pharmaceutical Industry (ABPI).
"This is undoubtedly a decision made in the best interests of people suffering from a variety of severe illnesses including Alzheimer's and Parkinson's," said Dr Trevor Jones, Director General of the ABPI.
"It would have been quite wrong if research into how we can help these people was prevented through fear of what action animal extremists might take. This centre will provide a golden opportunity for the UK to keep world-class scientists and stay at the forefront of research in these areas."
Only a very small amount of animal research is carried out with primates - less than 0.2 per cent of the total - but such work is essential if researchers are to be able to investigate how progress can be made in the field of neuro-science. This includes work on diseases such as Alzheimer's and Parkinson's, as well as vaccines against malaria and AIDS and how certain new medicines can be made suitable for testing in people.
For further information, please contact: ABPI Press Office 020 7747 1410